Last reviewed · How we verify
CoronaVac/BNT162b2
This is a combination COVID-19 vaccine regimen using CoronaVac (inactivated virus vaccine) followed by BNT162b2 (mRNA vaccine) to stimulate immune responses against SARS-CoV-2.
This is a combination COVID-19 vaccine regimen using CoronaVac (inactivated virus vaccine) followed by BNT162b2 (mRNA vaccine) to stimulate immune responses against SARS-CoV-2. Used for COVID-19 prevention (heterologous prime-boost regimen).
At a glance
| Generic name | CoronaVac/BNT162b2 |
|---|---|
| Sponsor | Institut Pasteur de Tunis |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CoronaVac is an inactivated whole-virus vaccine that primes the immune system with killed SARS-CoV-2 particles. BNT162b2 is an mRNA vaccine encoding the spike protein that provides a booster response. The heterologous prime-boost strategy aims to generate robust cellular and humoral immunity against multiple viral epitopes.
Approved indications
- COVID-19 prevention (heterologous prime-boost regimen)
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Community-based Sero-epidemiological Study of COVID-19
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity Induced by COVID-19 Vaccines in Mexican Population
- Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia) (PHASE3)
- Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
- The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoronaVac/BNT162b2 CI brief — competitive landscape report
- CoronaVac/BNT162b2 updates RSS · CI watch RSS
- Institut Pasteur de Tunis portfolio CI